Intravenous MRI contrast agents include chelates of paramagnetic ions, both ionic and nonionic. The particulates, sequestered in the liver, spleen, and lymph nodes, the intravascular agents, confined to the blood pool, and tumour specific agents are discusses separately (see bottom).
NOTE: This article has been transferred from mritutor.org and was last updated in March 5, 1996. Review and edit pending.
Paramagnetic metal ions suitable as MR contrast agents are all potentially toxic when injected IV at or near doses needed for clinical imaging. With chelation of these ions, acute toxicity is reduced and elimination rate is increased thereby reducing the chance of long term toxicity.
Chelates of paramagnetic ions Cr and Gd with EDTA were first used however EDTA was of relatively low stability resulting in toxicity in animals 1. Chelates with a higher stability constant have since been used successfully such as Gd-DTPA .
Gd-DTPA was the first intravenous MR contrast agent to be approved for human use (Magnevist, Berlex Labs). Gd has a large magnetic moment, exceeded only by Dysprosium(III) and Holmium(III), explaining its paramagnetic properties at low concentrations. This large magnetic moment is related to its seven unpaired orbital electrons. Gd-DTPA has similar pharmacokinetics as iodinated contrast agents. It is distributed in the intravascular and extracellular fluid spaces, does not cross an intact blood-brain-barrier, and is excreted rapidly by glomerular filtration 2.
The development of nonionic contrast agents for MRI has paralleled that for iodinated contrast materials. Ionic chelates are also hyperosmolar and some of their side effects may be attributed to this property.
Gadodiamide (Omniscan, Winthrop Pharm.) is a nonionic complex with two-fifths of the osmolality of Gd-DTPA. It has a median lethal dose of 34 mmol/kg resulting in a safety ratio of 2-3 times that of Gd-DOTA, and 3-4 times that of Gd-DTPA. No abnormal serum bilirubin levels occur, however elevated serum iron levels occurred with an incidence of 8.2% in one study of 73 patients.The efficacy of this contrast is similar to that of Gd-DTPA 3.
Gadoteridol (Prohance, Squibb) is the third intravenous contrast agent on the market. It is a low osmolar, nonionic contrast as is Gadodiamide. Indications for use and efficacy are similar to the other agents 4.
Intravenous MRI contrast agent safety
- MRI (introduction)
- MR physics
- MR hardware
- signal processing
MRI pulse sequences (basics | abbreviations | parameters)
- spin echo sequences
- inversion recovery sequences
- gradient echo sequences
- fat suppressed imaging sequences
- pulse sequence parameters
- diffusion weighted sequences (DWI)
- perfusion weighted imaging
- CSF flow studies
- susceptibility weighted imaging (SWI)
- saturation recovery sequences
- echo-planar pulse sequences
- metal artifact reduction sequence
- T1 rho
- spiral pulse sequences
- MR angiography (and venography)
MR spectroscopy (MRS)
- Hunter's angle
- lactate peak: resonates at 1.3 ppm
- lipids peak: resonate at 1.3 ppm
- alanine peak: resonates at 1.48 ppm
- N-acetylaspartate (NAA) peak: resonates at 2.0
- glutamine-glutamate peak: resonate at 2.2-2.4 ppm
- gamma-aminobutyric acid (GABA) peak: resonate at 2.2-2.4 ppm
- creatine peak: resonates at 3.0 ppm
- choline peak: resonates at 3.2 ppm
- myo-inositol peak: resonates at 3.5 ppm
- functional MRI
- MR hardware and room shielding
- MR software
- patient and physiologic motion
- tissue heterogeneity and foreign bodies
- Fourier transform and Nyqvist sampling theorem
MR contrast agents
- gadolinium ion
- extracellular MRI contrast agents
- hepatobiliary MRI contrast agents
- intravascular (blood pool) MRI contrast agents
- gastrointestinal MRI contrast agents
- tumor-specific MRI contrast agents
- reticuloendothelial MRI contrast agents
- contrast agent safety
- MR safety
- 1. Runge VM, Clanton JA, Herzer WA et-al. Intravascular contrast agents suitable for magnetic resonance imaging. Radiology. 1984;153 (1): 171-6. Radiology (abstract) - Pubmed citation
- 2. Runge VM, Schoerner W, Niendorf HP et-al. Initial clinical evaluation of gadolinium DTPA for contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 1985;3 (1): 27-35. Pubmed citation
- 3. Kaplan GD, Aisen AM, Aravapalli SR. Preliminary clinical trial of gadodiamide injection: a new nonionic gadolinium contrast agent for MR imaging. J Magn Reson Imaging. 1992;1 (1): 57-62. Pubmed citation
- 4. Runge VM, Dean B, Lee C et-al. Phase III clinical evaluation of Gd-HP-DO3A in head and spine disease. J Magn Reson Imaging. 1992;1 (1): 47-56. Pubmed citation